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Vascular Closure Device Failure
We Are Getting Better But Not There Yet*
Robert J. Applegate, MD
Winston-Salem, North Carolina
Manual compression for femoral artery access site hemosta-
sis had been the standard of care until the early 1990s. At
that time, 2 significant changes in clinical practice chal-
lenged the effectiveness of manual compression as the
optimal hemostasis method: the use of large-bore catheters
to perform coronary atherectomy, and intensive anticoagu-
lant regimens needed for the first clinical introduction of
intracoronary stents. At that time, large hematomas and
other vascular bleeding complications after coronary inter-
vention in these patients were commonplace and frustrating
to most interventionalists. In parallel, several devices under-
went development and final clinical approval to achieve
hemostasis more directly as an alternative to manual com-
pression. These vascular closure devices (VCDs) ushered in
a new error of vascular access management that has under-
gone extensive clinical evaluation and scrutiny.
See page 837
A suture-based device (Perclose, Abbott Vascular, Red-
wood City, California) and an extravascular collagen plug
(VasoSeal, Datascope, Mahwah, New Jersey) were intro-
duced for clinical application in 1994, whereas an intravas-
cular anchor and extravascular collagen sandwich, or collagen
plug (Angio-Seal, St Jude Medical, St Paul, Minnesota), was
approved for clinical use in 1996. The first versions of these
closure devices achieved hemostasis and shortened time to
ambulation in most patients in whom they were used. How-
ever, device failure requiring immediate or delayed manual
compression still occurred in up to 10% to 20% of these
patients. Since the initial versions of the closure devices were
made available for clinical use, both the Perclose and the
Angioseal devices have undergone extensive modifications to
address issues of device failure. For example, in the 1,000-
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edical and Terumo Corporation.patient Angio-Seal Evolution registry, using the most recent
collagen plug device in an all-comers 10-center prospective
registry, device-mediated immediate hemostasis was achieved
in 99% of uses (1). In this issue of JACC: Cardiovascular
Interventions, Vidi et al. (2) report a 93.9% success rate with the
suture-based device as reported in a Massachusetts Depart-
ment of Health registry. Interestingly, although modifications
were made to the extravascular collagen plug device to enhance
its effectiveness, observations from 2 meta-analyses of clinical
outcomes with VCDs in 2004 indicated an increased risk of
vascular complications with the device compared with manual
compression and ultimately led to the withdrawal of this
product from the marketplace (3,4).
The consequences of closure device failure would seem
self-evident, particularly in the percutaneous coronary inter-
vention (PCI) patient. However, the extent and severity of
associated bleeding or other vascular complications is poten-
tially affected by many variables, including the size of the
arteriotomy as well as the presence and extent of anticoagula-
tion. In a patient who has undergone simple diagnostic cardiac
catheterization with a small caliber sheath, failure to achieve
immediate hemostasis with a VCD is treated with manual
compression, often leading to successful hemostasis and
minimal bleeding or other vascular complications. However,
in the setting of PCI where a VCD is placed at the end of the
procedure in a patient still effectively anticoagulated, the
potential extent and severity of bleeding and/or other vascular
complications are expected to be much higher. Despite these
presumptions, there are only limited data that evaluate issues
relevant to VCD failure.
Vidi et al. also evaluated the frequency and predictors of
VCD deployment failure as well as bleeding and vascular
complications observed in these patients from 23,813 con-
secutive interventional coronary procedures as identified
from a dataset from the Massachusetts Department of
Health (2). Between June 2005 and December 2007, there
were 18,533 collagen plug VCDs, 2,996 suture-based
VCDs, and 2,284 nitinol clip-based VCDs used for femoral
artery hemostasis after PCI. Overall, VCD failure occurred
in 3.3% of procedures with failure rates of 2.1% with
collagen-based VCD, 6.1% with suture-based VCD, and
9.5% with nitinol clip-based VCD. As expected, VCD
failures were associated with an increased risk of vascular
complications compared with those in whom the VCD was
successfully deployed for all types of vascular complications
assessed. In a subsequent subgroup analysis using a propen-
sity score–adjusted evaluation, the authors evaluated the
relative likelihood of VCD failure and observed a 2-fold
increased risk with the nitinol clip-based VCD and 1.25-
fold increased risk with a suture-based VCD compared with
the collagen plug-based device. Interestingly VCD failure
was a significant predictor of vascular complications for the
collagen plug-based VCD as well as the nitinol clip-based
VCD but not for the suture-based VCD.
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846There are a few aspects of this study that merit further
discussion. The observations from this analysis provide a
contemporary standard for the frequency of VCD failure
and its association with vascular complications. As acknowl-
edged by the authors, VCD failure is uncommon but is
associated with a significant increase in the incidence of a
vascular complication. There also seems to be variability in
the likelihood that a vascular complication will occur after
VCD failure, depending on the type of VCD used. Despite
a significantly lower rate of VCD failure, the collagen
plug-based VCD was associated with a statistically higher
rate of any vascular complication than either the nitinol
clip-based or suture-based VCD (2.1% vs. 6.1% and 9.5%
respectively, p  0.001), due primarily to a statistically
higher rate of major vascular complications.
This apparent dissociation between a very low rate of
device failure and a higher rate of overall vascular compli-
cation is unexpected. The reason(s) for this apparent dichot-
omy are not readily apparent. There are clear differences in
the number of patients treated with the different devices
(80% collagen plug-based VCD) as well as baseline clinical
characteristics. Although the authors appropriately applied
propensity score matching methodology to adjust for these
differences, the ultimate impact of these potential biases
remains unclear. Another source of difference might have
occurred with the study definition of complications. The
authors hypothesized that vascular complications might
have been lower with the suture-based VCD, because a
bailout strategy exists for this device—where an additional
device could be deployed or a sheath reinserted—but not for
the other 2 devices. Although this is plausible, we would
need to know how often this occurred and whether this
strategy “counted” as a vascular complication. Finally, there
is an association between a “high femoral artery stick” and
use of a VCD after PCI, resulting in an increased incidence
of vascular complications (5). The extent to which this
occurred and with which device might have also influenced
the study outcomes. However, there are no data available to
address this issue.
The observation of the authors naturally leads one to
compare the “superiority” of 1 VCD with another. There
has been long-standing interest in the efficacy and safety of
VCDs compared with manual compression as well as
whether 1 particular VCD is safer and associated with lower
vascular complications than another. With respect to the
issue of the safety of VCDS compared with manual com-
pression, a number of small randomized trials have been
performed, and multiple large registries have been published
showing a consistent decrease in the association of vascular
complications with VCDs compared with manual compres-
sion. Biancari et al. (6) incorporated some of these more
recent randomized clinical trials in a meta-analysis and were
not able to demonstrate increased safety with VCDs com-pared with manual compression, despite modifications in
the closure devices leading to decreased rates of device
failure at the time of implantation. These data and the
absence of the definitive large randomized clinical trial led
to a Class III indication for VCD use to decrease bleeding
after a coronary intervention, no benefit, in the most recent
2011 American Heart Association/American College of
Cardiology/Society for Cardiovascular Angiography and
Interventions PCI guidelines update (7). In these same
guidelines, no recommendation was made as to device-
specific safety, and it has been the type of study by Vidi et al.
in this issue that have shaped interventionalist perception of
device-specific safety.
What should we take away from this study? First, VCD
failure rates are lower than for the original version of each
of the devices. However, failure rates of almost 10%, as
observed with the nitinol clip-based device, would be
unacceptable for any other device used during a PCI
procedure. Clearly, opportunities for improvement in the
safety and performance of these closure devices still remain.
Second, comparison of the relative safety of these devices is
problematic. The dissociation between the incidence of
device failure in fully anticoagulated patients and the inci-
dence of overall vascular complication remains unexplained
and weakens the conclusions that can be drawn about the
relative safety of these devices. Third, from a clinical
perspective, it would have been useful to provide informa-
tion on the timing of the vascular complication (i.e., at
deployment or after leaving the laboratory), because this
might have provided insights into the mechanism of failure.
Understanding the reason for VCD failure is paramount to
developing better and more effective devices. Finally, that
these data are coming from an observational registry and not
a randomized clinical trial underscores the strong need of
appropriately powered and designed clinical trials to address
the efficacy and safety of closure devices.
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